Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2009

View Archived Issues

Weight loss seen in one-year studies of velneperit in obese subjects

AMPA receptor potentiator PF-4778574 safe and active in preclinical models of cognition

NOP receptor agonist SCH-655842 exhibits anxiolytic activity in preclinical models

SUVN-623 shows promising activity in animal models of cognition

Nicotinic alpha4beta2 receptor modulator A-969933 alters the stimulant effects of nicotine

Results reported for phase I clinical trial of new slow-release metadoxine

Dong-A PharmTech starts phase III trials of udenafil in men with erectile dysfunction

FDA grants orphan drug designation to Sunesis' voreloxin for acute myeloid leukemia

FDA advisory committee to review Theratechnologies' NDA for tesamorelin

Ligand Pharmaceuticals and Pfizer extend research collaboration for JAK3

InterMune submits NDA to FDA for pirfenidone in idiopathic pulmonary fibrosis

Immunovaccine and Canadian military collaborate to develop anthrax vaccine

FDA approves labeling update for Reyataz to include 96-week CASTLE data

Dipeptidyl peptidase IV inhibitors claimed by Taiwanese scientists as antidiabetics

Helix completes enrollment in phase II topical interferon alpha-2b trial

Raf kinase inhibitors disclosed by Wyeth for the treatment of cancer

BMS describes serine protease inhibitors for treating thromboembolic disorders

ERYtech Pharma starts pivotal trial of Graspa in acute lymphoblastic leukemia

FDA approves Gloucester's Istodax for cutaneous T-cell lymphoma

FDA approves Pennsaid topical solution for osteoarthritis of the knee

Theravance and Astellas Pharma launch telavancin in the U.S.

Novexel initiates phase II clinical trial of NXL-103 in bacterial skin infections

Shire launches Intuniv in the U.S. for ADHD in children and adolescents

Phase I study finds potential for rontalizumab in systemic lupus erythematosus

AIDS Vaccine meeting snapshots: Phase I and II trials of candidate vaccines

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026